{"id":988,"date":"2023-12-17T13:00:01","date_gmt":"2023-12-17T13:00:01","guid":{"rendered":"https:\/\/ventil.rs\/blog\/health\/the-weight-loss-drug-boom-isnt-over-yet-heres-what-to-expect-in-the-year-ahead\/"},"modified":"2023-12-17T13:00:01","modified_gmt":"2023-12-17T13:00:01","slug":"the-weight-loss-drug-boom-isnt-over-yet-heres-what-to-expect-in-the-year-ahead","status":"publish","type":"post","link":"https:\/\/ventil.rs\/blog\/health\/the-weight-loss-drug-boom-isnt-over-yet-heres-what-to-expect-in-the-year-ahead\/","title":{"rendered":"The weight loss drug boom isn’t over yet \u2014 here’s what to expect in the year ahead"},"content":{"rendered":"


\n<\/p>\n

<\/p>\n
\n
\n
\n

George Frey | Bloomberg | Getty Images<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n

Weight loss drugs<\/a> exploded into the public eye this year, and 2024 will bring more change to the evolving market.\u00a0<\/p>\n

The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags<\/a>, mixed insurance coverage<\/a> and a handful of unpleasant side effects<\/a>.\u00a0<\/p>\n

Demand for the drugs is unlikely to slow down in 2024, especially as treatments gradually become more accessible. Much of Wall Street believes the weight loss drug market will only expand, with some analysts<\/a> projecting that it will be worth $100 billion<\/a> by the end of the decade.\u00a0Goldman Sachs analysts expect 15 million U.S. adults<\/a> to be on obesity medications by 2030.<\/p>\n

But next year, investors will be watching how the dominant players in the market, Novo Nordisk<\/a>